I see that you remain meticulous in your research and reporting, a trait I have always respected in you. I appreciate the information you provided in regards to the Ireland subsidiary (although subsidiary may be too generous of a description, though Field Office may under estimate whatever is going on over there).
Point of order in regards to comments you made about the last time our paths crossed. I did not initially post on Ihub about that other company. I posted on another board. So my comments were based on much more than two days of experience as a shareholder, and regarded my thought that the next quarterly filing may show earnings of $1.25. The company subsequently provided guidance, and estimated the very number I had. There was a split involved in that discussion as well, as I recall. And since you decided to reference my research in regards to that other company, it seemed to be good enough for my judicial appointment as the shareholders' Estate Representative, which I accepted but never even asked for. The judge granted me subpoena power which I used to obtain Electronic Blue Sheet trading records from FINRA in that case. The company's main clearing firm, Penson Financial, was a focus of my research, and they were subsequently charged and convicted of Naked Shorting. To the shareholders here, so you don't think otherwise, I am not a lawyer, and did not hire a lawyer to help me in that case.
In terms of what I'm looking for with IPIX, the answer is upside potential. I'm still holding the balance of my shares in HGEN. I had a small number of shares I purchased in 2017. But I began a more serious accumulation of shares this year, starting in the 90 cent range. That stock is currently valued at over $21. I think brilacidin is more versatile than HGEN's lenzilumab, and that IPIX may follow HGEN's performance. If so, my favorite way to trade is to maintain a core position, and to trade the remainder of it.
